In case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
OncoTherapy Network Staff
This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.
Identifying gene signatures in patients with clear cell renal cell carcinoma (ccRCC) that can predict the likelihood of their disease metastasizing, as well as the site of metastasis, may help to better stratify risk assessment for the disease and plan appropriate treatment strategies.
This slide show features images of melanoma, basal cell carcinoma, squamous cell carcinoma, as well as images of metastatic disease.
This slide show features pathology slides and PET/CT scans of prostate cancer, as well as various images of bone lesions from metastatic disease.
This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
It seems as though we are seeing more news reports lately on the rising cost of cancer drugs—specifically targeted therapy drugs. Some are even going as far as to ask cancer patients and survivors to sign a petition in hopes of lobbying Congress so that government officials can negotiate lower prices with pharmaceutical companies.
In a study with mice and cells taken from human patients with B-cell precursor acute lymphoblastic leukemia (BPL), a combined molecule involving the CD19 receptor and a protein called sTRAIL, showed potent anti-leukemic activity. The “fusion protein” created was far more potent than sTRAIL alone.